Silvan Turkcan
Stock Analyst at Citizens JMP
(1.33)
# 3,905
Out of 4,698 analysts
8
Total ratings
50%
Success rate
-1.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Turkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintained: Buy | $42 | $39.97 | +5.08% | 1 | Aug 6, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $3 | $0.363 | +726.45% | 1 | Aug 6, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $80 | $56.49 | +41.62% | 1 | Jul 22, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $51 | $39.00 | +30.77% | 1 | Jul 20, 2026 | |
| CELC Celcuity | Maintained: Buy | $160 → $177 | $96.43 | +83.55% | 3 | Jul 15, 2026 | |
| HURA TuHURA Biosciences | Initiated Coverage: Buy | $9 | $2.10 | +328.57% | 1 | Apr 27, 2026 |
IDEAYA Biosciences
Aug 6, 2026
Maintained: Buy
Price Target: $42
Current: $39.97
Upside: +5.08%
Context Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $3
Current: $0.363
Upside: +726.45%
CRISPR Therapeutics AG
Jul 22, 2026
Maintained: Buy
Price Target: $80
Current: $56.49
Upside: +41.62%
Faeth Therapeutics
Jul 20, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $39.00
Upside: +30.77%
Celcuity
Jul 15, 2026
Maintained: Buy
Price Target: $160 → $177
Current: $96.43
Upside: +83.55%
TuHURA Biosciences
Apr 27, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $2.10
Upside: +328.57%